Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Natera initiated with an Outperform at Credit Suisse » 16:41
08/24/22
08/24
16:41
08/24/22
16:41
NTRA

Natera

$52.03 /

+1.73 (+3.44%)

Credit Suisse analyst Dan…

Credit Suisse analyst Dan Leonard initiated coverage of Natera with an Outperform rating and $70 price target. The analyst has a positive view of the company's growth opportunities in minimal residual disease testing across multiple indications, as well as its "continued leading position" in reproductive health testing.

ShowHide Related Items >><<
NTRA Natera
$52.03 /

+1.73 (+3.44%)

NTRA Natera
$52.03 /

+1.73 (+3.44%)

08/17/22 Piper Sandler
Natera price target raised to $70 from $60 at Piper Sandler
08/05/22 JPMorgan
Natera price target raised to $100 from $80 at JPMorgan
07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
NTRA Natera
$52.03 /

+1.73 (+3.44%)

NTRA Natera
$52.03 /

+1.73 (+3.44%)

NTRA Natera
$52.03 /

+1.73 (+3.44%)

Recommendations
Natera price target raised to $70 from $60 at Piper Sandler » 21:42
08/17/22
08/17
21:42
08/17/22
21:42
NTRA

Natera

$52.53 /

-2.595 (-4.71%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg raised the firm's price target on Natera to $70 from $60 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings.

ShowHide Related Items >><<
NTRA Natera
$52.53 /

-2.595 (-4.71%)

NTRA Natera
$52.53 /

-2.595 (-4.71%)

08/05/22 JPMorgan
Natera price target raised to $100 from $80 at JPMorgan
07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
NTRA Natera
$52.53 /

-2.595 (-4.71%)

NTRA Natera
$52.53 /

-2.595 (-4.71%)

NTRA Natera
$52.53 /

-2.595 (-4.71%)

Hot Stocks
Natera completes enrollment in RenaCARE study » 07:33
08/11/22
08/11
07:33
08/11/22
07:33
NTRA

Natera

$55.22 /

+4.39 (+8.64%)

Natera announced full…

Natera announced full enrollment for the RenaCARE study, a real world, prospective, multi-center clinical study to assess the clinical utility of Natera's Renasight genetic testing panel, which analyzes more than 380 genes related to kidney disease. Enrollment in the study was completed early as a result of statistically meaningful interim data analysis. The study includes more than 1,700 patients across 30+ sites, representing leading academic and private nephrology clinics in the U.S. A publication for the RenaCARE study is expected to be submitted in early 2023.

ShowHide Related Items >><<
NTRA Natera
$55.22 /

+4.39 (+8.64%)

NTRA Natera
$55.22 /

+4.39 (+8.64%)

08/05/22 JPMorgan
Natera price target raised to $100 from $80 at JPMorgan
07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
NTRA Natera
$55.22 /

+4.39 (+8.64%)

NTRA Natera
$55.22 /

+4.39 (+8.64%)

NTRA Natera
$55.22 /

+4.39 (+8.64%)

Hot Stocks
Natera announces Q-Sub filing with FDA for its Panorama NIPT » 16:19
08/10/22
08/10
16:19
08/10/22
16:19
NTRA

Natera

$55.22 /

+4.39 (+8.64%)

Natera announced earlier…

Natera announced earlier at the Canaccord Genuity 42nd Annual Growth Conference in Boston that the company has proactively filed a pre-submission to the FDA for its Panorama non-invasive prenatal test as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and for 22q11.2 deletion syndrome.

ShowHide Related Items >><<
NTRA Natera
$55.22 /

+4.39 (+8.64%)

NTRA Natera
$55.22 /

+4.39 (+8.64%)

08/05/22 JPMorgan
Natera price target raised to $100 from $80 at JPMorgan
07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
NTRA Natera
$55.22 /

+4.39 (+8.64%)

NTRA Natera
$55.22 /

+4.39 (+8.64%)

NTRA Natera
$55.22 /

+4.39 (+8.64%)

On The Fly
Sell these stocks now, proven algorithm says » 13:43
08/05/22
08/05
13:43
08/05/22
13:43
ROKU

Roku

$83.31 /

+2.02 (+2.48%)

, SHAK

Shake Shack

$51.33 /

+0.35 (+0.69%)

, RCL

Royal Caribbean

$40.12 /

+0.66 (+1.67%)

, CCL

Carnival

$9.91 /

+0.165 (+1.69%)

, PING

Ping Identity

$27.95 /

-0.04 (-0.14%)

, COMP

Compass

$4.03 /

+0.125 (+3.20%)

, DWAC

Digital World Acquisition

$31.90 /

+0.27 (+0.85%)

, RXRX

Recursion Pharmaceuticals

$9.70 /

+0.105 (+1.09%)

, NXE

NexGen Energy

$4.25 /

+0.065 (+1.55%)

, IRT

Independence Realty Trust

$20.92 /

-0.04 (-0.19%)

, ULCC

Frontier Group

$14.40 /

+0.1 (+0.70%)

, PL

Planet Labs

$5.76 /

-0.06 (-1.03%)

, TDOC

Teladoc

$37.17 /

-0.33 (-0.88%)

, TLRY

Tilray

$3.91 /

-0.12 (-2.98%)

, PAR

Par Technology

$43.90 /

-0.13 (-0.30%)

, TMDX

TransMedics

$46.56 /

+5.185 (+12.53%)

, NTRA

Natera

$51.84 /

+0.94 (+1.85%)

, PTRA

Proterra

$6.43 /

+0.555 (+9.45%)

Each week, The Fly will…

ShowHide Related Items >><<
ULCC Frontier Group
$14.40 /

+0.1 (+0.70%)

TMDX TransMedics
$46.56 /

+5.185 (+12.53%)

TLRY Tilray
$3.91 /

-0.12 (-2.98%)

TDOC Teladoc
$37.17 /

-0.33 (-0.88%)

SHAK Shake Shack
$51.33 /

+0.35 (+0.69%)

RXRX Recursion Pharmaceuticals
$9.70 /

+0.105 (+1.09%)

ROKU Roku
$83.31 /

+2.02 (+2.48%)

RCL Royal Caribbean
$40.12 /

+0.66 (+1.67%)

PTRA Proterra
$6.43 /

+0.555 (+9.45%)

PL Planet Labs
$5.76 /

-0.06 (-1.03%)

PING Ping Identity
$27.95 /

-0.04 (-0.14%)

NXE NexGen Energy
$4.25 /

+0.065 (+1.55%)

NTRA Natera
$51.84 /

+0.94 (+1.85%)

IRT Independence Realty Trust
$20.92 /

-0.04 (-0.19%)

DWAC Digital World Acquisition
$31.90 /

+0.27 (+0.85%)

COMP Compass
$4.03 /

+0.125 (+3.20%)

CCL Carnival
$9.91 /

+0.165 (+1.69%)

ROKU Roku
$83.31 /

+2.02 (+2.48%)

08/03/22 Citi
Roku price target lowered to $125 from $165 at Citi
08/01/22 Morgan Stanley
Roku price target lowered to $55 from $80 at Morgan Stanley
07/29/22 BofA
BofA double downgrades Roku with headwinds seen lasting 2-3 quarters
07/29/22 BofA
Roku downgraded to Underperform from Buy at BofA
SHAK Shake Shack
$51.33 /

+0.35 (+0.69%)

07/19/22 Gordon Haskett
Shake Shack initiated with a Hold at Gordon Haskett
07/18/22 Morgan Stanley
Shake Shack price target lowered to $48 from $63 at Morgan Stanley
07/13/22 Cowen
Shake Shack price target lowered to $52 from $70 at Cowen
07/08/22 Wedbush
Wedbush sees Dine Brands, Wingsstop, Wendy's as Best Ideas in restaurants
RCL Royal Caribbean
$40.12 /

+0.66 (+1.67%)

07/29/22 Wells Fargo
Royal Caribbean price target lowered to $58 from $81 at Wells Fargo
07/29/22 Deutsche Bank
Royal Caribbean price target lowered to $48 from $50 at Deutsche Bank
07/29/22 Susquehanna
Royal Caribbean price target lowered to $50 from $70 at Susquehanna
06/29/22 Barclays
Barclays initiates cruise line space with Royal Caribbean top pick
CCL Carnival
$9.91 /

+0.165 (+1.69%)

07/22/22 Truist
Carnival price target lowered to $8 from $15 at Truist
07/21/22 Stifel
Carnival selloff 'coming for sure' as equity raise will cause panic, says Stifel
07/04/22 HSBC
HSBC says too early to call inflection point for Carnival
06/29/22 Morgan Stanley
Morgan Stanley cuts Carnival price target to $7, sees bear case of zero
PING Ping Identity
$27.95 /

-0.04 (-0.14%)

08/04/22 DA Davidson
Ping Identity downgraded to Neutral from Buy at DA Davidson
08/04/22 Stephens
Ping Identity downgraded to Equal Weight from Overweight at Stephens
08/04/22 Barclays
Ping Identity downgraded to Equal Weight from Overweight at Barclays
08/04/22 BTIG
Ping Identity downgraded to Neutral from Buy at BTIG
COMP Compass
$4.03 /

+0.125 (+3.20%)

07/21/22 Morgan Stanley
Compass downgraded to Equal Weight from Overweight at Morgan Stanley
05/16/22 Oppenheimer
Compass price target lowered to $9 from $14 at Oppenheimer
04/22/22 Zelman
Compass initiated with a Hold at Zelman
03/30/22 Goldman Sachs
Compass price target lowered to $12 from $21 at Goldman Sachs
DWAC Digital World Acquisition
$31.90 /

+0.27 (+0.85%)

RXRX Recursion Pharmaceuticals
$9.70 /

+0.105 (+1.09%)

04/18/22 BofA
Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
03/04/22 SVB Securities
Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
09/21/21 Berenberg
Recursion Pharmaceuticals initiated with a Buy at Berenberg
NXE NexGen Energy
$4.25 /

+0.065 (+1.55%)

05/25/22 Raymond James
NexGen Energy removed from Analyst Current Favorites list at Raymond James
04/22/22 Canaccord
NexGen Energy price target raised to C$10.75 from C$10 at Canaccord
04/11/22 RBC Capital
NexGen Energy upgraded to Outperform from Sector Perform at RBC Capital
03/03/22 Raymond James
NexGen Energy price target raised to C$9 from C$8.50 at Raymond James
IRT Independence Realty Trust
$20.92 /

-0.04 (-0.19%)

06/30/22 Jefferies
Independence Realty Trust price target lowered to $24 from $27 at Jefferies
05/10/22 Barclays
Independence Realty Trust price target lowered to $28 from $30 at Barclays
05/09/22 BTIG
Independence Realty Trust assumed with a Buy at BTIG
04/22/22 Jefferies
Independence Realty Trust initiated with a Buy at Jefferies
ULCC Frontier Group
$14.40 /

+0.1 (+0.70%)

08/02/22 BofA
Frontier Group resumed with a Buy at BofA
07/12/22 Susquehanna
Frontier Group price target lowered to $13 from $15 at Susquehanna
06/27/22 Evercore ISI
Frontier Group price target lowered to $15 from $20 at Evercore ISI
06/23/22 Raymond James
Frontier Group upgraded to Outperform from Market Perform at Raymond James
PL Planet Labs
$5.76 /

-0.06 (-1.03%)

06/15/22 Craig-Hallum
Planet Labs price target lowered to $10 from $15 at Craig-Hallum
06/15/22 Needham
Planet Labs price target lowered to $8.00 from $10.50 at Needham
06/15/22 Benchmark
Planet Labs price target lowered to $11 from $15 at Benchmark
05/25/22 Benchmark
EOCL award watershed moment for BlackSky, GIS industry, says Benchmark
TDOC Teladoc
$37.17 /

-0.33 (-0.88%)

08/02/22 Berenberg
Berenberg downgrades Teladoc to Hold on 'underwhelming execution'
08/02/22 Cowen
Teladoc downgraded to Market Perform from Outperform at Cowen
07/29/22 Deutsche Bank
Teladoc price target lowered to $34 from $44 at Deutsche Bank
07/28/22 Stifel
Teladoc price target lowered to $30 from $36 at Stifel
TLRY Tilray
$3.91 /

-0.12 (-2.98%)

07/29/22 Cowen
Tilray price target lowered to $9 from $23 at Cowen
07/29/22 Benchmark
Tilray cut to Sell at Benchmark on continued deterioration in core business
07/29/22 Benchmark
Tilray downgraded to Sell from Hold at Benchmark
07/15/22 Roth Capital
Tilray price target lowered to $4 from $8 at Roth Capital
PAR Par Technology
$43.90 /

-0.13 (-0.30%)

05/23/22 Jefferies
Par Technology price target lowered to $43 from $55 at Jefferies
05/17/22 Goldman Sachs
Par Technology initiated with a Neutral at Goldman Sachs
03/02/22 Craig-Hallum
Par Technology price target lowered to $60 from $100 at Craig-Hallum
01/26/22 BTIG
Par Technology price target lowered to $60 from $110 at BTIG
TMDX TransMedics
$46.56 /

+5.185 (+12.53%)

08/02/22 Cowen
TransMedics price target raised to $50 from $45 at Cowen
08/02/22 Oppenheimer
TransMedics price target raised to $45 from $40 at Oppenheimer
08/02/22 JPMorgan
TransMedics upgraded on 'highly attractive' opportunity at JPMorgan
08/02/22 Canaccord
TransMedics price target raised to $58 from $46 at Canaccord
NTRA Natera
$51.84 /

+0.94 (+1.85%)

08/05/22 JPMorgan
Natera price target raised to $100 from $80 at JPMorgan
07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
PTRA Proterra
$6.43 /

+0.555 (+9.45%)

06/01/22 DA Davidson
Proterra initiated with a Buy at DA Davidson
05/19/22 Barclays
Proterra price target lowered to $6 from $8 at Barclays
05/16/22 Citi
Proterra price target lowered to $6.50 from $8.50 at Citi
05/13/22 BofA
Proterra double downgraded to Underperform at BofA
ULCC Frontier Group
$14.40 /

+0.1 (+0.70%)

TMDX TransMedics
$46.56 /

+5.185 (+12.53%)

TLRY Tilray
$3.91 /

-0.12 (-2.98%)

TDOC Teladoc
$37.17 /

-0.33 (-0.88%)

SHAK Shake Shack
$51.33 /

+0.35 (+0.69%)

RXRX Recursion Pharmaceuticals
$9.70 /

+0.105 (+1.09%)

ROKU Roku
$83.31 /

+2.02 (+2.48%)

RCL Royal Caribbean
$40.12 /

+0.66 (+1.67%)

PTRA Proterra
$6.43 /

+0.555 (+9.45%)

PL Planet Labs
$5.76 /

-0.06 (-1.03%)

PING Ping Identity
$27.95 /

-0.04 (-0.14%)

PAR Par Technology
$43.90 /

-0.13 (-0.30%)

NTRA Natera
$51.84 /

+0.94 (+1.85%)

IRT Independence Realty Trust
$20.92 /

-0.04 (-0.19%)

COMP Compass
$4.03 /

+0.125 (+3.20%)

CCL Carnival
$9.91 /

+0.165 (+1.69%)

  • 05
    Aug
  • 21
    Jul
  • 09
    Nov
  • 15
    Sep
  • 16
    Aug
  • 10
    Oct
ULCC Frontier Group
$14.40 /

+0.1 (+0.70%)

TLRY Tilray
$3.91 /

-0.12 (-2.98%)

TDOC Teladoc
$37.17 /

-0.33 (-0.88%)

SHAK Shake Shack
$51.33 /

+0.35 (+0.69%)

ROKU Roku
$83.31 /

+2.02 (+2.48%)

RCL Royal Caribbean
$40.12 /

+0.66 (+1.67%)

NTRA Natera
$51.84 /

+0.94 (+1.85%)

DWAC Digital World Acquisition
$31.90 /

+0.27 (+0.85%)

CCL Carnival
$9.91 /

+0.165 (+1.69%)

ULCC Frontier Group
$14.40 /

+0.1 (+0.70%)

TMDX TransMedics
$46.56 /

+5.185 (+12.53%)

TLRY Tilray
$3.91 /

-0.12 (-2.98%)

TDOC Teladoc
$37.17 /

-0.33 (-0.88%)

SHAK Shake Shack
$51.33 /

+0.35 (+0.69%)

RXRX Recursion Pharmaceuticals
$9.70 /

+0.105 (+1.09%)

ROKU Roku
$83.31 /

+2.02 (+2.48%)

RCL Royal Caribbean
$40.12 /

+0.66 (+1.67%)

PTRA Proterra
$6.43 /

+0.555 (+9.45%)

PL Planet Labs
$5.76 /

-0.06 (-1.03%)

PING Ping Identity
$27.95 /

-0.04 (-0.14%)

NXE NexGen Energy
$4.25 /

+0.065 (+1.55%)

NTRA Natera
$51.84 /

+0.94 (+1.85%)

DWAC Digital World Acquisition
$31.90 /

+0.27 (+0.85%)

COMP Compass
$4.03 /

+0.125 (+3.20%)

CCL Carnival
$9.91 /

+0.165 (+1.69%)

TLRY Tilray
$3.91 /

-0.12 (-2.98%)

TDOC Teladoc
$37.17 /

-0.33 (-0.88%)

SHAK Shake Shack
$51.33 /

+0.35 (+0.69%)

ROKU Roku
$83.31 /

+2.02 (+2.48%)

RCL Royal Caribbean
$40.12 /

+0.66 (+1.67%)

PL Planet Labs
$5.76 /

-0.06 (-1.03%)

DWAC Digital World Acquisition
$31.90 /

+0.27 (+0.85%)

COMP Compass
$4.03 /

+0.125 (+3.20%)

CCL Carnival
$9.91 /

+0.165 (+1.69%)

COMP Compass
$4.03 /

+0.125 (+3.20%)

Recommendations
Natera price target raised to $100 from $80 at JPMorgan » 07:15
08/05/22
08/05
07:15
08/05/22
07:15
NTRA

Natera

$50.94 /

+1.965 (+4.01%)

, UNH

UnitedHealth

$533.65 /

-7.25 (-1.34%)

JPMorgan analyst Julia…

JPMorgan analyst Julia Qin raised the firm's price target on Natera (NTRA) to $100 from $80 and keeps an Overweight rating on the shares. Natera reported solid 2Q results and expanded reimbursement meaningfully boosts its revenue outlook, Qin tells investors in a research note. The company was also recently included in UnitedHealth's (UNH) preferred lab network, a further testament to Natera's "leading operating standards," says the analyst. She believes the company "continues to fire on all cylinders across the portfolio."

ShowHide Related Items >><<
UNH UnitedHealth
$533.65 /

-7.25 (-1.34%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
05/06/22 Cowen
Natera price target lowered to $100 from $110 at Cowen
UNH UnitedHealth
$533.65 /

-7.25 (-1.34%)

07/25/22 Argus
UnitedHealth price target raised to $650 from $580 at Argus
07/21/22 UBS
UnitedHealth price target raised to $570 from $545 at UBS5
07/20/22 BMO Capital
UnitedHealth price target raised to $610 from $600 at BMO Capital
07/19/22 Deutsche Bank
UnitedHealth price target raised to $556 from $549 at Deutsche Bank
UNH UnitedHealth
$533.65 /

-7.25 (-1.34%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

UNH UnitedHealth
$533.65 /

-7.25 (-1.34%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

UNH UnitedHealth
$533.65 /

-7.25 (-1.34%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

UNH UnitedHealth
$533.65 /

-7.25 (-1.34%)

Earnings
Natera raises FY22 revenue view to $805M-$825M from $790M-$810M » 16:59
08/04/22
08/04
16:59
08/04/22
16:59
NTRA

Natera

$50.94 /

+1.965 (+4.01%)

FY22 consensus $805.18M.…

FY22 consensus $805.18M. "Strong momentum driven by record volume levels enabled us to again raise our 2022 revenue guidance," said Steve Chapman, Natera's CEO. "We are proud to have served close to 500,000 patients in Q2. As we scale the business, we now see a clear path to reach a cash flow breakeven quarter by mid-2024. A key highlight in the quarter was receiving Medicare coverage for Signatera in muscle-invasive bladder cancer, representing the fourth coverage decision by Medicare for Signatera."

ShowHide Related Items >><<
NTRA Natera
$50.94 /

+1.965 (+4.01%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
05/06/22 Cowen
Natera price target lowered to $100 from $110 at Cowen
NTRA Natera
$50.94 /

+1.965 (+4.01%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

Earnings
Natera reports Q2 EPS ($1.50), consensus ($1.50) » 16:57
08/04/22
08/04
16:57
08/04/22
16:57
NTRA

Natera

$50.94 /

+1.965 (+4.01%)

Reports Q2 revenue…

Reports Q2 revenue $198.2M, consensus $193.7M.

ShowHide Related Items >><<
NTRA Natera
$50.94 /

+1.965 (+4.01%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
05/06/22 Cowen
Natera price target lowered to $100 from $110 at Cowen
NTRA Natera
$50.94 /

+1.965 (+4.01%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

NTRA Natera
$50.94 /

+1.965 (+4.01%)

Hot Stocks
Natera says Federal Circuit affirms September 2021 decision on CareDx patents » 13:38
07/18/22
07/18
13:38
07/18/22
13:38
NTRA

Natera

$44.24 /

-1.575 (-3.44%)

, CDNA

CareDx

$22.72 /

-0.18 (-0.79%)

Natera (NTRA) announced…

Natera (NTRA) announced that the Federal Circuit Court of Appeals affirmed the Delaware Federal District Court's September 2021 decision that all three CareDx (CDNA) patents asserted against Natera are invalid for claiming patent-ineligible subject matter. "We are pleased that multiple courts have rejected CareDx's baseless claims against Natera's proprietary technology," said Daniel Rabinowitz, chief legal officer, Natera. "Natera is a leading innovator of cfDNA testing, and we remain focused on serving the transplant community, including our many physician partners and patients."

ShowHide Related Items >><<
NTRA Natera
$44.24 /

-1.575 (-3.44%)

CDNA CareDx
$22.72 /

-0.18 (-0.79%)

NTRA Natera
$44.24 /

-1.575 (-3.44%)

07/18/22 Piper Sandler
Natera CMS decision will drive more tests, says Piper Sandler
07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
05/06/22 Cowen
Natera price target lowered to $100 from $110 at Cowen
CDNA CareDx
$22.72 /

-0.18 (-0.79%)

04/25/22 Stephens
CareDx initiated with an Overweight at Stephens
02/28/22 BTIG
CareDx price target lowered to $65 from $100 at BTIG
02/25/22 Craig-Hallum
CareDx price target lowered to $87 from $106 at Craig-Hallum
02/25/22 Raymond James
CareDx price target lowered to $52 from $90 at Raymond James
NTRA Natera
$44.24 /

-1.575 (-3.44%)

CDNA CareDx
$22.72 /

-0.18 (-0.79%)

  • 22
    Jul
NTRA Natera
$44.24 /

-1.575 (-3.44%)

NTRA Natera
$44.24 /

-1.575 (-3.44%)

Recommendations
Natera CMS decision will drive more tests, says Piper Sandler » 09:40
07/18/22
07/18
09:40
07/18/22
09:40
NTRA

Natera

$45.82 /

+0.005 (+0.01%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg reiterates an Overweight rating on Natera with a $60 price target after the company received written communication that Centers for Medicare and Medicaid Services updated its coverage decision on Signatera to include muscle invasive bladder cancer. The coverage decision validates CMS' willingness to pay for tests outside of colorectal cancer and in the intermediate term it will help Natera generate more tests at a higher selling price, Westenberg tells investors in a research note. The analyst calls molecular residual disease assay the "Goldilocks market of oncology," and he thinks Natera's "first mover advantage will prove to be fruitful."

ShowHide Related Items >><<
NTRA Natera
$45.82 /

+0.005 (+0.01%)

NTRA Natera
$45.82 /

+0.005 (+0.01%)

07/14/22 Piper Sandler
Piper says Natera selection for UnitedHealth network validates practices
05/15/22 Piper Sandler
Natera price target lowered to $60 from $75 at Piper Sandler
05/06/22 Cowen
Natera price target lowered to $100 from $110 at Cowen
05/06/22 Baird
Natera price target lowered to $71 from $100 at Baird
NTRA Natera
$45.82 /

+0.005 (+0.01%)

  • 22
    Jul
NTRA Natera
$45.82 /

+0.005 (+0.01%)

NTRA Natera
$45.82 /

+0.005 (+0.01%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.